Kenpaullone, a commonly used KLF4 inhibitor in basic study, has been shown to significantly downregulate the mRNA and protein levels of KLF4 in various models, including canine mammary tumor (Tien et al., 2015),non-Hodgkin lymphoma (Montecillo-Aguado et al., 2021) and autoimmune arthritis (Choi et al., 2018). The gene discussed is KLF4; the disease is non-Hodgkin lymphoma.